Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders

Abstract

Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.

Plasma levels of S100B and neurofilament light chain protein in stress-related mental disorders

“…Previous research in an animal model has shown that SSRIs may prevent psychosocial stress from reducing the number of astrocytes in the hippocampus 41 . This finding is consistent with observations that antidepressant medication can reduce levels of S100B in serum 18 , 42 . It is thus possible that the patients in the current study would have had higher levels of S100B if they had not been taking antidepressants.…”

Plasma biomarkers in adolescents with schizophrenia‐spectrum disorder

“…seems to be involved in several clinical states like depression (Rajewska-Rager et al, 2021) or trauma (Falcone et al, 2015), what limits its specificity.…”

“…No. : DY248, DY3175, DY367, DY1820-05, respectively) DuoSet ELISA Development Kits (R&D System, Minneapolis, MN, USA) according to the manufacturer's instructions, with minor modifications, as described previously (Rajewska-Rager et al, 2021). The standard curve ranges were 1500-23.4 pg/ mL (BDNF), 5000-78.1 pg/mL (proBDNF), 3000-46.9 pg/mL (NGFR), 2000-31.2 pg/mL (S100B).…”

Plasma Biomarkers in Early-Onset Schizophrenia. Case-Control Study in Adolescent Population

“…No. : DY248, DY3175, DY367, DY1820-05, respectively) DuoSet ELISA Development Kits (R&D System, Minneapolis, MN, USA) according to the manufacturer's instructions, with minor modi cations, as described previously (42). The standard curve ranges were 1500-23.4 pg/ml (BDNF), 5000-78.1 pg/ml (proBDNF), 3000-46.9 pg/ml (NGFR), 2000 − 31.2 pg/ml (S100B).…”

“…S100B was also indicated as potential suicide marker in CSF post-mortem studies(59). In children and adolescent population, S100B seems to be involved in several clinical states like depression(42) or trauma (60), what limits its speci city.4.2. Executive functioning and BDNF pathwayExcepting the potential biomarker value, BDNF pathway has been analyzed in relation to executive functioning.…”